A transformative approach
Fully integrated with end-to-end capabilities
Legend Biotech operates with a global network to efficiently and rapidly develop cell therapies from discovery through commercialization
Robust, global research and development infrastructure and pipeline
- We focus our research and development on the areas of greatest unmet need
- We have one of the world’s largest internal discovery research engines (>250 scientists and engineers dedicated to cell therapy R&D) with employees recruited from leading laboratories
- Our dedicated R&D teams based in China, Ireland, and the United States are working to develop potential best-in-class proprietary technology platforms
- By design, our CAR-T, TCR-T, and allogeneic platforms are complementary and customizable
- Speed to market is enhanced by our global integrated R&D model and infrastructure
Rapidly advancing clinical assets
- Accelerating development and speed to market of our clinical compounds through global partnerships
- Partnering with leading clinicians in their respective fields to rapidly advance our pipeline and platforms
- Reducing clinical program risk by leveraging data through our global R&D network
- Attracting global talent with extensive experience in all stages of clinical development
- Maintaining focus on quality and compliance throughout clinical development
Established global manufacturing network
- With two US and one China manufacturing facilities capable of producing clinical and commercial CAR-T supplies, we are equipped to meet the demands of LCAR-B38M/JNJ-4528* and our pipeline assets
- We are working with industry-leading technologies and service providers to innovate the CAR-T manufacturing process, optimize the end-to-end supply chain, and streamline the product delivery model
Manufacturing Sites
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
*LCAR-B38M identifies the investigational product being studied in China and Janssen Biotech, Inc.’s JNJ-68284528 (also referenced as JNJ-4528) identifies the investigational product being studied in the United States, both of which are representative of the same CAR-T cell therapy.
Expanding our commercial footprint
- We are building our commercial infrastructure and footprint for LCAR-B38M/ JNJ-4528* as part of our collaboration with Janssen Biotech, Inc.
- The established commercial capabilities and infrastructure will pave the way for our future pipeline products
- We have hired and continue to recruit top talent with extensive oncology experience launching and commercializing CAR-T and other blockbuster brands
- Strategically building the most efficient and effective go-to-market model to maximize the reach of cell therapy
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
*LCAR-B38M identifies the investigational product being studied in China and Janssen Biotech, Inc.’s JNJ-68284528 (also referenced as JNJ-4528) identifies the investigational product being studied in the United States, both of which are representative of the same CAR-T cell therapy.
